StockNews.com began coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a report published on Tuesday. The brokerage issued a sell rating on the stock. Separately, Mizuho reaffirmed a neutral rating and set a $3.50 price target on shares of Corvus Pharmaceuticals in a research report on Thursday, March 30th. Corvus Pharmaceuticals Stock […]
StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research note issued to investors on Tuesday morning. The firm issued a sell rating on the stock. Separately, Mizuho restated a neutral rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research note on Thursday, March […]
StockNews.com began coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a report released on Monday. The brokerage issued a sell rating on the stock. Separately, Mizuho reaffirmed a neutral rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Thursday, March 30th. Corvus Pharmaceuticals Price […]
StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a report released on Monday. The brokerage issued a sell rating on the stock. Separately, Mizuho reissued a neutral rating and set a $3.50 price objective on shares of Corvus Pharmaceuticals in a report on Thursday, March 30th. Corvus Pharmaceuticals Stock Performance […]
Equities researchers at StockNews.com initiated coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research note issued on Monday. The brokerage set a “sell” rating on the stock. Separately, Mizuho reaffirmed a “neutral” rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research note on Thursday, March […]